根据向美国证券交易委员会（SEC）提交的文件，生物制药公司CalciMedica Inc.已与其贷款方达成协议，对现有贷款条款进行了重要修订。
此次修订的核心内容包括两项关键延期。首先，贷款的仅付息期被延长至2027年9月30日。在此期限内，公司只需支付贷款利息，无需偿还本金，这将显著缓解其近期的现金流压力。其次，贷款的整体最终到期日也被推迟至2029年9月1日，为公司提供了更长的资金运作和研发窗口。
这一财务安排的调整，为CalciMedica推进其临床阶段管道项目，特别是针对急性胰腺炎和哮喘等适应症的CRAC通道抑制剂研发，提供了更为灵活和稳定的资金支持。协议的达成，通常反映了贷款方对公司长期发展前景的认可，也体现了公司在当前市场环境下积极管理财务结构的努力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.